Comorbidity-Associated N-Glycome Profile Shifts: A Preliminary Study Evaluating COPD and Diabetes in Lung Cancer Patients
5 affiliations
- 1Research Institute of Biomolecular and Chemical Engineering, University of Pannonia, 8200 Veszprém, Hungary
- 2Department of Pulmonology, Borsod-Abaúj-Zemplén County Central Hospital and University Teaching Hospital, 3526 Miskolc, Hungary
- 3Faculty of Health Sciences, University of Miskolc, 3515 Miskolc, Hungary
- 4Bio-Nanosystems Laboratory, Faculty of Engineering, University of Pannonia, 8200 Veszprém, Hungary
- 5Horváth Csaba Memorial Laboratory of Bioseparation Sciences, Center for Translational Medicine, Doctoral School of Molecular Medicine, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary
Abstract
Aberrant glycosylation frequently accompanies malignant, metabolic, and chronic inflammatory diseases; however, it remains unclear how coexisting conditions influence disease-associated alterations in serum N-glycan profiles. To address this question, this preliminary study examined the influence of chronic obstructive pulmonary disease (COPD) and diabetes mellitus (DM) on the N-glycan profiles in 40 patients with lung cancer (LC), divided into four groups (LC, LC + DM, LC + COPD, and LC + COPD + DM; n = 10 each). Released and fluorescently labelled N-glycans were profiled by capillary electrophoresis using laser-induced fluorescence detection. Peaks with a median relative peak area of ≥1% across the complete dataset were retained for quantitative analysis, resulting in a final set of 19 peaks. Peak-wise factorial models assessed DM, COPD, and their interaction while accounting for age and sex. When the peaks were analyzed individually, Peak 12, tentatively assigned to A3G(4)3S(6)2 by GU database matching (median GU 7.23), was the only peak that remained significant after multiple-testing correction. Descriptively, its mean relative peak area (%) was approximately 21% higher in DM-positive patients, while the adjusted model confirmed DM association on the logit scale. Likewise, analysis of the 19-peak serum N-glycan profile revealed a significant association with DM, whereas no significant effect of COPD or DM × COPD interaction was detected. F(6)A2B showed an exploratory DM-associated signal but did not remain significant after conventional multiple-testing correction. Our findings suggest that diabetes may be associated with a modest but detectable shift in the serum N-glycome profile of patients with lung cancer, with A3G(4)3S(6)2 representing the strongest structure-specific finding in this cohort. However, please note that under the more stringent joint correction across all 57 peak-effect tests, the HC3-based Peak 12 result did not reach the conventional significance threshold (FDR q = 0.055).
Related
- Clinical characteristics and preliminary discriminatory value of low triiodothyronine syndrome in patients with peritoneal dialysis-associated peritonitis : A cross-sectional study
- Autologous Peripheral Blood-Derived Stem Cells Combined with Platelet-Rich Plasma is Associated With Clinical and Radiological Improvement in Anterior Cruciate Ligament Ruptures—Preliminary Clinical and MRI Findings in 47 Consecutive Patients
- Machine‐Learning Prediction of Tumor Comorbidity and Cancer‐Associated Mortality in Patients With Coronary Heart Disease: A 2‐Stage Modeling Study
- Evaluating Gates’ GFR accuracy in renal tumor patients through integration of standalone CT-derived renal depth estimation via deep learning segmentation: a preliminary study
- The Effect of Advanced Platelet-Rich Fibrin on the Healing of Post-Extraction Sockets in Patients with Diabetes: Preliminary Findings from a Randomized Controlled Clinical Trial
BibTeX
@article{kiss2026comorbidityassociated,
title = {{Comorbidity-Associated N-Glycome Profile Shifts: A Preliminary Study Evaluating COPD and Diabetes in Lung Cancer Patients}},
author = {Beatrix Kiss and Rebeka Török and Miklós Szabó and Eszter Csánky and Ilona Slárku and Erika Malyik and Zsófia Robotka and Álmos Kádár and Sara Sardou and Gábor Járvás and András Guttman},
journal = {Cancers},
year = {2026},
month = nov,
doi = {10.3390/cancers18213530},
url = {https://www.mdpi.com/2072-6694/18/21/3530},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Comorbidity-Associated N-Glycome Profile Shifts: A Preliminary Study Evaluating COPD and Diabetes in Lung Cancer Patients
AU - Beatrix Kiss
AU - Rebeka Török
AU - Miklós Szabó
AU - Eszter Csánky
AU - Ilona Slárku
AU - Erika Malyik
AU - Zsófia Robotka
AU - Álmos Kádár
AU - Sara Sardou
AU - Gábor Járvás
AU - András Guttman
PY - 2026
DA - 2026/11/03
JO - Cancers
DO - 10.3390/cancers18213530
UR - https://www.mdpi.com/2072-6694/18/21/3530
AB - Aberrant glycosylation frequently accompanies malignant, metabolic, and chronic inflammatory diseases; however, it remains unclear how coexisting conditions influence disease-associated alterations in serum N-glycan profiles. To address this question, this preliminary study examined the influence of chronic obstructive pulmonary disease (COPD) and diabetes mellitus (DM) on the N-glycan profiles in 40 patients with lung cancer (LC), divided into four groups (LC, LC + DM, LC + COPD, and LC + COPD + DM; n = 10 each). Released and fluorescently labelled N-glycans were profiled by capillary electrophoresis using laser-induced fluorescence detection. Peaks with a median relative peak area of ≥1% across the complete dataset were retained for quantitative analysis, resulting in a final set of 19 peaks. Peak-wise factorial models assessed DM, COPD, and their interaction while accounting for age and sex. When the peaks were analyzed individually, Peak 12, tentatively assigned to A3G(4)3S(6)2 by GU database matching (median GU 7.23), was the only peak that remained significant after multiple-testing correction. Descriptively, its mean relative peak area (%) was approximately 21% higher in DM-positive patients, while the adjusted model confirmed DM association on the logit scale. Likewise, analysis of the 19-peak serum N-glycan profile revealed a significant association with DM, whereas no significant effect of COPD or DM × COPD interaction was detected. F(6)A2B showed an exploratory DM-associated signal but did not remain significant after conventional multiple-testing correction. Our findings suggest that diabetes may be associated with a modest but detectable shift in the serum N-glycome profile of patients with lung cancer, with A3G(4)3S(6)2 representing the strongest structure-specific finding in this cohort. However, please note that under the more stringent joint correction across all 57 peak-effect tests, the HC3-based Peak 12 result did not reach the conventional significance threshold (FDR q = 0.055).
SN - 2072-6694
ER -